A massive transfusion protocol (MTP) 
In trauma patients, coagulopathy frequently develops that contributes to the duration and severity of hemorrhage and is associated with an increased risk of death. 1, 2 Transfusing platelets, plasma, and/or cryoprecipitate early and often during massive transfusion may reduce the frequency or severity of coagulopathy and thereby improve survival. 2, 3 The level 1 trauma program at Grant Medical Center, Columbus, OH, treats approximately 4,500 adult patients a year. In January 2006 the program implemented a massive transfusion protocol (MTP) that called for automatic administration of plasma in addition to RBCs for resuscitation of hemorrhaging trauma patients. The MTP was modified in 2007 to a 1:1:1 RBC-plasma-platelet balanced resuscitation. Both protocols required the submission of samples for platelet count, fibrinogen level, and prothrombin time (PT) at defined points in the transfusion sequence. After obtaining institutional review board approval, the clinical and laboratory records for all trauma patients for whom an MTP was activated from January 2006 through February 2009 were reviewed. The frequency and nature of abnormal tests indicative of coagulopathy were determined and correlated with the MTP used and the transfusions actually administered.
This article describes the findings and reports whether and how the more aggressive use of non-RBC transfusions under the updated protocol affected the patients' clotting profiles and RBC transfusion requirements. This analysis did not address patient outcomes.
Materials and Methods
The MTPs were designed for patients who used an initial 6 U of uncrossmatched packed RBCs within an hour in the presence of continuing bleeding or who were admitted with exsanguinating hemorrhage. The trauma surgeon and anesthesiologist were authorized to activate the MTP. Under the MTP, blood components were issued in sets ("trauma packs"). From January 2006 through August 2007, the trauma pack consisted of 4 U of RBCs and 2 U of plasma. In September 2007, the trauma pack was modified to 4 U of RBCs, 4 U of plasma, and a dose of platelets ❚Table 1❚. The patients were not randomized as to the MTP; rather the same protocol was used for all massive transfusions within the stated periods.
Group O Rh-RBCs and group AB plasma and platelets were used until the patient's blood type could be determined. When needed to avoid depleting inventory, RBCs were switched to group O Rh+ if the patient was male or older than 50 years (unless the patient was known to have a history of anti-D). Once the patient's blood type was determined, ABOidentical or ABO-compatible RBCs and plasma-compatible platelets and plasma (eg, group A for a group O patient) were issued except that plasma-incompatible platelets were used when necessary based on available inventory. Each adult dose of platelets was provided as a pool of 4 whole blood-derived concentrates that, based on the blood supplier quality control testing, contained approximately 3 × 10 11 platelets. When required owing to limited availability of whole blood-derived platelets, 1 U of apheresis platelets was substituted. Both RBC and platelet components were leukoreduced as part of manufacturing by the blood supplier. The transfusion service kept at least 2 platelet doses and 4 U of thawed AB plasma in inventory at all times to allow rapid response when the MTP was initiated. Consequently, the first 4 plasma transfusions were with "thawed plasma," which has lower but hemostatic levels of coagulation factors VIII and V. 4 Subsequent plasma transfusions consisted of newly thawed plasma frozen within 24 hours.
The transfusion service technologists monitored the results of the laboratory testing and automatically prepared and issued platelets, additional plasma, and/or cryoprecipitate to supplement the trauma pack if the test results exceeded preestablished levels indicative of coagulopathy (laboratorydriven transfusion). While the treating physician could order additional components if needed based on assessment of the patient's bleeding, this was seldom done.
For the study, transfusion and laboratory records were analyzed in detail for the first 12 hours of treatment-a sufficiently long observation time during which the development and progression of coagulopathy could be observed. Analysis was limited to the subgroup of patients who survived at least 12 hours (early survivors) to prevent bias from patients who died of their overwhelming injuries before intended transfusions (especially of non-RBC components) could be administered. The types and numbers of transfusions to the early survivors were identified, the total transfusion volumes were determined, and the RBC/plasma ratios were calculated. The results of laboratory tests for coagulation were correlated with the number of minutes since the start of transfusion resuscitation, beginning with the issue time of the first component(s), which was most often the initial 6 U of uncrossmatched RBCs. A patient was defined as having coagulopathy if the platelet count was less than 50 × 10 3 /μL (50 × 10 9 /L), the fibrinogen was less than 100 mg/dL (2.9 μmol/L), and/or the PT was 16 seconds or more.
Data for the original and new protocol early survivor groups were compared by using the Fisher exact test with respect to nominal variables and the Wilcoxon rank sum test with respect to numeric variables. Lowess curves were used to examine trends in laboratory values over time. Comparisons with P values less than .05 were considered to represent significant differences. Data were analyzed using SAS, version 9.1 (SAS Institute, Cary, NC) and R, version 1.9.1 (R Foundation for Statistical Computing; www.r-project.org).
Results
Forty-five patients were treated according to the original MTP, of whom 25 (56%) survived at least 12 hours, and 50 patients were treated according to the new MTP, of whom 27 (54%) survived at least 12 hours (P = 1.0). The following observations apply to these 52 early survivors ❚Table 2❚. The groups were comparable in terms of type of trauma, mode of injury, sex, Injury Severity Score (ISS), and length of stay in intensive care and in the hospital. The patients in the new protocol group were, on average, approximately 8 years older than patients in the original protocol group (not statistically significant, P = .10). Six patients, all treated according to the new protocol, received recombinant activated factor VII (rVIIa) as part of their resuscitation (P = .02). None of the patients received antifibrinolytics.
Compared with the original protocol, a higher proportion of patients received plasma, and the mean plasma transfusion volume was increased under the new protocol ❚Table 3❚. Significantly more patients received high-plasma-content therapy, defined as an RBC-to-plasma ratio of 1.9 or less, under the new protocol (13/27 [48%] vs 3/25 [12%]; P = .0067), although a majority of patients in both groups still received low-plasma-content therapy (RBC-to-plasma ratio of 2.0 or greater). Similarly, more patients received platelets under the new protocol, and the mean platelet transfusion volume was higher. The transfusion rates and volumes for cryoprecipitate (which was not a component of either MTP "recipe") were also higher under the new protocol (P = .01). Despite the increased numbers of platelet, plasma, and cryoprecipitate transfusions, the numbers of RBC units transfused (as a gross indicator of the severity of coagulopathy) were not lower under the new protocol. Patients treated under the new protocol received an average of 1,643 mL more in total transfusion volume (P = .0031). There was a large range of individual test results at each time point. Based on the trend curves, the hemoglobin levels were higher after the first 100 minutes with the original protocol (P < .01) ❚Figure 1❚. Fibrinogen levels and platelet counts fell and PTs were prolonged in the first approximately 100 minutes under both protocols and to comparable degrees (P = .803, P = .550, and P = .899, respectively) ❚Figure 2❚, ❚Figure 3❚, and ❚Figure 4❚. Of the 52 patients who survived ❚Figure 4❚ Prothrombin times (seconds) over time for the 25 patients treated under the original protocol (dots and solid line) and 27 patients treated under the new protocol (boxes and dashed line) who survived at least 12 hours. One patient in the original protocol group and 4 patients in the new protocol group had ≥1 prothrombin times that were longer than 120 seconds; these data points are not shown. MTP, massive transfusion protocol. at least 12 hours, 39 (75%) became coagulopathic, usually within the first 2 hours (23 [59%] of 39) ❚Table 4❚. There were no statistically significant differences in the proportions of patients who became coagulopathic during the first hour (acute), between 1 and 2 hours (early), and between 2 and 12 hours (late) according to the MTP (P = .054). The most frequent first laboratory indicator of coagulopathy was a fibrinogen level less than 100 mg/dL (2.9 μmol/L) (36 of 39), and most of the coagulopathies were fully corrected within the first 12 hours, regardless of the MTP.
Discussion
As many as 1 in 4 multiple trauma patients are admitted with an early-onset coagulopathy that is characterized by fibrinogen consumption, possibly as a result of unchecked fibrinolysis. 5 In the 5% to 10% who receive massive transfusions of RBCs, which contain only small amounts of plasma and no functioning platelets, dilutional coagulation factor and platelet deficiencies also develop that can be compounded by infusion of large volumes of asanguinous resuscitation fluids. [6] [7] [8] [9] Furthermore, trauma patients are often acidotic and hypothermic, an environment in which coagulation protein and platelet function are impaired. 1 The combination of fibrinolysis, dilution, and inadequate function produces a complex coagulopathy in many trauma patients who receive massive transfusions. 1,2 By defining coagulopathy as a PT or activated partial thromboplastin time more than twice normal, Cosgriff et al 2 found coagulopathy in 47% of trauma patients who received 10 or more RBC transfusions in 24 hours and in nearly all patients with an ISS of more than 25, a pH less than 7.1, a systolic blood pressure of less than 70 mm Hg, or a temperature less than 34ºC. While thrombocytopenia developed in only 2.1% of trauma patients who received 9 U of RBCs or fewer (platelet count, <50 × 10 3 /μL [50 × 10 9 /L]), Huber-Wagner et al 9 reported that the incidence rose in proportion to the transfusion volume to a high of 21.8% in patients who received 30 U of RBCs or more.
Trauma patients in whom coagulopathy develops have increased mortality, and it is thought that the coagulopathy contributes to the mechanism of death in some cases (exsanguinations) and serves as a marker of more serious injury in other cases. [9] [10] [11] To the degree that trauma coagulopathy contributes to the mechanism of death, aggressive transfusion therapy with plasma, platelets, and/or cryoprecipitate could prevent or promptly correct deficiencies and thereby might improve survival. Indeed, multiple trauma programs have achieved dramatically increased survival rates when more units of plasma and, less often, platelets, were transfused with RBCs during massive transfusion. [12] [13] [14] [15] None of these studies was randomized, and most were retrospective case reviews of a notoriously complex patient situation with many injury and treatment features that affect outcome. Although assumed, it is not well documented how or whether these non-RBC transfusions change the frequency, severity, or duration of trauma coagulopathy. 16 Most reports do not include laboratory test results, blood loss rates, or other parameters that might reflect improved hemostasis.
To address this question, the laboratory assessment of coagulation as an indicator of the effect of a plasma-rich MTP became the focus of this study. Since periodic laboratory testing of coagulation parameters has been part of our massive transfusion protocols, we were able to determine whether and when our patients became coagulopathic and to analyze the effect of 2 different massive transfusion approaches.
We found that, even though patients treated under the new protocol received more plasma and platelets and a higher proportion ultimately received high plasma resuscitation (RBC/plasma ratio ≤1.9), the coagulopathies and RBC requirements were indistinguishable from those in patients treated under the original protocol. Under both protocols, the levels of fibrinogen and platelets fell and the PT increased during the first approximately 100 minutes, at which point the values began correcting toward baseline (fibrinogen, platelets, and PT) or leveled off (platelets). In our patients, fibrinogen deficiency, which is characteristic of the early coagulopathy of trauma, was usually the first clotting abnormality, and it developed in a majority of patients (36 of 52) who survived at least 12 hours. Regardless of protocol and initial indicator of coagulopathy, nearly all of our patients were no longer coagulopathic at 12 hours.
The 6 early survivors who received rVIIa were all treated under the new protocol. This drug shortens PT and international normalized ratio values but does not affect the platelet count or fibrinogen level. 17 The role of rVIIa in the treatment of traumatic hemorrhage is still under discussion. 18 At Parkland Hospital, Dallas, TX, the massive transfusion protocol was modified to include rVIIa and cryoprecipitate with every fourth transfusion "pack" in addition to platelets in every third pack and 2 U of plasma for each 5 U of RBCs in each pack. While the change was not associated with increased survival compared with historic controls, hemostasis was improved in the 132 study patients so that the RBC transfusion volumes were reduced and the total treatment cost was several thousand dollars less despite the rVIIa cost. 19 In our new protocol cohort, the recipients of rVIIa received more of all types of components, including RBCs (average, 29.3 vs 14.9 U), and were more likely to have received high plasma resuscitation (50% vs 37%) compared with patients treated under the new protocol who did not receive rVIIa. This subgroup is too small to draw any conclusions about benefits of the drug. The transfusion volumes were higher probably because rVIIa was reserved for patients in whom the standard transfusion approach had been tried (and tried again) and was not working in contrast with the protocol at Parkland in which rVIIa was automatically included at defined points in the resuscitation.
There are several possible explanations for the lack of difference in the coagulation profiles between the 2 groups. The patients were not randomized as to MTP, and there is undoubtedly an uneven distribution of patient, injury, and treatment variables that might have affected the coagulation profiles, even though the demographics, ISS, and injury types and mechanisms were comparable. The group of 52 early survivors following massive transfusion may not be large enough to extract this level of detail. It is possible that differences would become apparent only later in the hospital course, although the coagulopathic exsanguination risk occurs early, often within the first 6 hours of treatment, which would imply that the clotting abnormalities are well established by then. 20 The incremental non-RBC transfusions under the new protocol (5 U of plasma, 1 U of platelets, and 1 U of cryoprecipitate on average) may not have been large enough to affect the results of laboratory coagulation tests in these complex trauma patients, even though in other patient groups, these transfusion volumes would be expected to measurably increase platelet and fibrinogen levels and reduce clotting times. We might have been particularly successful at managing coagulopathy under our laboratory-driven original protocol so that automatic transfusion of plasma and platelets offered little improvement. Despite the comparable ISS, types of trauma, and modes of injury, the patients treated under the new protocol may have been more seriously injured and destined to have worse coagulopathies than the original protocol cohort, except that the increased non-RBC transfusions maintained their clotting profiles comparable to those of the less seriously injured patients treated under the original protocol. Perhaps the processes that determine clotting status in trauma patients are not simple dilution and consumption, both of which should be amenable to transfusion therapy.
Even though a protocol update resulted in an increased number of non-RBC transfusions to patients receiving massive transfusion for trauma, the associated coagulopathy was unchanged. If there is a survival benefit to increased non-RBC transfusions in trauma patients receiving massive transfusions, the mechanism may not simply be restoring the integrity of the clotting system. Other hypotheses, such as a reduction in the volume of resuscitation fluids that decrease in inverse proportion to the transfusion volume, should continue to be investigated.
